Sprache: Englisch
Verlag: Nova Science Publishers Inc, 2012
ISBN 10: 1613246390 ISBN 13: 9781613246399
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
EUR 113,22
Anzahl: 2 verfügbar
In den WarenkorbHRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.
Sprache: Englisch
Verlag: Nova Science Publishers Inc, 2012
ISBN 10: 1613246390 ISBN 13: 9781613246399
Anbieter: PBShop.store US, Wood Dale, IL, USA
HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.
Sprache: Englisch
Verlag: Nova Science Publishers Inc, 2012
ISBN 10: 1613246390 ISBN 13: 9781613246399
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. Editor(s): Dickson, Jonathan R.; Woebler, Amy M. Num Pages: 147 pages, illustrations. BIC Classification: MBN; MMG. Category: (P) Professional & Vocational. Dimension: 232 x 157 x 14. Weight in Grams: 376. . 2012. Hardcover. . . . . Books ship from the US and Ireland.
Sprache: Englisch
Verlag: Nova Science Publishers Inc, 2012
ISBN 10: 1613246390 ISBN 13: 9781613246399
Anbieter: moluna, Greven, Deutschland
Gebunden. Zustand: New. Examines prescription drug pricing costs and control concerns with a focus on extraordinary price increases for brand-name prescription drugs, as well as the characteristics and factors that contributed to this price increase.Klappentextrnrn.
Sprache: Englisch
Verlag: Nova Science Publishers Inc Feb 2012, 2012
ISBN 10: 1613246390 ISBN 13: 9781613246399
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. Neuware - The growing cost of brand-name prescription drugs can be a burden on patients, payers and providers of health care, particularly when price increases are large and occur suddenly. Controlling rising prescription drug prices helps to ensure that patients can afford medically necessary and sometimes life-saving medication, and to moderate costs for hospitals and third-party payers such as insurance plans and state and federal governments. This book examines prescription drug pricing costs and control concerns with a focus on extraordinary price increases for brand-name prescription drugs, as well as the characteristics and factors that contributed to this price increase.